Nkarta signs 12-year lease for 88,106 sq ft manufacturing and HQ facility in South San Francisco

Nkarta, Inc.

Monthly base rent starts at ~$564K, escalating to ~$823K; tenant improvement allowance up to $25.2M.
Facility will support research, development, and commercial manufacturing of NK cell therapy pipeline.
Expected operational by end of 2023; planned production for pivotal trials and commercial launch.
Nkarta retains existing 2,700 sq ft cGMP facility for early-stage clinical manufacturing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.